Unifying the Epidemiological and Evolutionary Dynamics of Pathogens
|
journal
|
January 2004 |
Analysis of Hepatitis C Virus Superinfection Exclusion by Using Novel Fluorochrome Gene-Tagged Viral Genomes
|
journal
|
February 2007 |
Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing
|
journal
|
July 2015 |
The role of mutational robustness in RNA virus evolution
|
journal
|
March 2013 |
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
|
journal
|
March 2015 |
Superinfection Exclusion in Cells Infected with Hepatitis C Virus
|
journal
|
February 2007 |
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
|
journal
|
May 2010 |
Influence of Viral Replication Mechanisms on Within-Host Evolutionary Dynamics: Influence of Viral Replication Mechanisms on Within-Host Evolutionary Dynamics
|
journal
|
June 2012 |
Evasion of Superinfection Exclusion and Elimination of Primary Viral RNA by an Adapted Strain of Hepatitis C Virus
|
journal
|
October 2013 |
Viral Quasispecies Evolution
|
journal
|
June 2012 |
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration
|
journal
|
May 2011 |
Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver
|
journal
|
April 2014 |
Mathematical Analysis of HIV-1 Dynamics in Vivo
|
journal
|
January 1999 |
The role of cells refractory to productive infection in acute hepatitis B viral dynamics
|
journal
|
March 2007 |
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
|
journal
|
December 2011 |
MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
|
journal
|
May 2012 |
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
|
journal
|
May 2010 |
Vacated niches, competitive release and the community ecology of pathogen eradication
|
journal
|
August 2013 |
In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance
|
journal
|
August 2015 |
Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration
|
journal
|
October 2013 |
Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing
|
journal
|
August 2012 |
Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate
|
journal
|
August 2012 |
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
|
journal
|
May 2008 |
Inferring Viral Dynamics in Chronically HCV Infected Patients from the Spatial Distribution of Infected Hepatocytes
|
journal
|
November 2014 |
A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
|
journal
|
April 2010 |
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs
|
journal
|
December 2002 |
Combination of a Hepatitis C Virus NS3-NS4A Protease Inhibitor and Alpha Interferon Synergistically Inhibits Viral RNA Replication and Facilitates Viral RNA Clearance in Replicon Cells
|
journal
|
November 2004 |
Viral and Cellular Determinants of Hepatitis C Virus RNA Replication in Cell Culture
|
journal
|
March 2003 |
Low Dynamic State of Viral Competition in a Chronic Avian Hepadnavirus Infection
|
journal
|
June 2000 |
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study
|
journal
|
October 2016 |
Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication
|
journal
|
December 2002 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
|
journal
|
December 2015 |
Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance
|
journal
|
May 2017 |
Protease Inhibitor–Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious Virus
|
journal
|
February 2011 |
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin
|
journal
|
December 2014 |
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy
|
journal
|
October 1998 |
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
|
journal
|
February 2013 |
Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
|
journal
|
March 2013 |
Pre–existence and emergence of drug resistance in HIV–1 infection
|
journal
|
May 1997 |
Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics
|
journal
|
December 2010 |
Antibody neutralization and escape by HIV-1
|
journal
|
March 2003 |
Genetic recombination of the hepatitis C virus: clinical implications: Impacts of HCV recombination
|
journal
|
September 2010 |
Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach
|
journal
|
April 2015 |
Avoiding the void: cell-to-cell spread of human viruses
|
journal
|
November 2008 |
The Outcome of Hepatitis C Virus Infection Is Predicted by Escape Mutations in Epitopes Targeted by Cytotoxic T Lymphocytes
|
journal
|
December 2001 |
Modeling Viral Spread
|
journal
|
September 2016 |
Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection
|
journal
|
June 2015 |
A perspective on modelling hepatitis C virus infection: A perspective on modelling HCV infection
|
journal
|
August 2010 |
Beneficial Mutation–Selection Balance and the Effect of Linkage on Positive Selection
|
journal
|
May 2007 |
Pre-existence and emergence of drug resistance in a generalized model of intra-host viral dynamics
|
journal
|
December 2012 |
Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection
|
journal
|
September 2014 |
Identification, Molecular Cloning, and Analysis of Full-Length Hepatitis C Virus Transmitted/Founder Genotypes 1, 3, and 4
|
journal
|
February 2015 |
Evolutionary Analysis of Human Immunodeficiency Virus Type 1 Therapies Based on Conditionally Replicating Vectors
|
journal
|
October 2012 |
Influenza A Virus Uses Intercellular Connections To Spread to Neighboring Cells
|
journal
|
November 2014 |
Antiretroviral dynamics determines HIV evolution and predicts therapy outcome
|
journal
|
September 2012 |
Use of Laser Capture Microdissection to Map Hepatitis C Virus–Positive Hepatocytes in Human Liver
|
journal
|
December 2013 |
Global control of hepatitis C: where challenge meets opportunity
|
journal
|
July 2013 |
Origin and Evolution of the Unique Hepatitis C Virus Circulating Recombinant Form 2k/1b
|
journal
|
November 2011 |